Search Results - "Moesenthin, Michael"

Real‐world study: Escalating targeted lipid‐lowering treatment with PCSK9‐inhibitors and lipoprotein apheresis by Spitthöver, Ralf, Röseler, Tilmann, Julius, Ulrich, Heigl, Franz, Schettler, Volker J. J., Kühn, Ralf, Leebmann, Josef, Raabe, Andrea, Knittel, Markus, Schürfeld, Carsten, Moesenthin, Michael, Bernhardt, Wanja M., Röseler, Eberhard, Ketteler, Markus, Heibges, Andreas, Klingel, Reinhard

“…Introduction Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with monoclonal antibodies has complemented the armamentarium of lipid‐lowering…”
Get full text

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases by WRENGER, Eike, MÜLLER, Regina, MOESENTHIN, Michael, WELTE, Tobias, FRÖLICH, Jürgen G, NEUMANN, Klaus H

“…The randomised aldactone evaluation study (RALES) proved a substantial (30%) reduction in risk of mortality in patients with severe congestive heart failure by…”
Get full text

Lesson Of The Week: Interaction Of Spironolactone With Ace Inhibitors Or Angiotensin Receptor Blockers: Analysis Of 44 Cases by Wrenger, Eike, Müller, Regina, Moesenthin, Michael, Welte, Tobias, Frölich, Jürgen C., Neumann, Klaus H.

Get full text

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases by Wrenger, Eike, Müller, Regina, Moesenthin, Michael, Welte, Tobias, Frölich, Jürgen C, Neumann, Klaus H

“…Part of the renal insufficiency in our patients was reversible as on discharge the creatinine clearance improved from a mean of 0.38(SD 0.22) ml/s to 0.65…”
Get full text